Research programme: small molecule therapeutics - BridGene Biosciences/Galapagos
Latest Information Update: 13 Aug 2024
At a glance
- Originator BridGene Biosciences; Galapagos NV
- Developer BridGene Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors; Rho GTP-binding protein inhibitors; Transcription factor inhibitors; WDR5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Aug 2024 BridGene Biosciences expands strategic collaboration with Galapagos to develop selective oral SMARCA2 PROTAC
- 03 Jan 2024 BridGene Biosciences and Galapagos agree to co-promote and co-develop small molecule therapeutics for Cancer
- 05 Jan 2022 BridGene Biosciences plans to file an IND application with the US FDA for Cancer in 2023